NVDA vs PFE: Which Is the Better Buy?
Side-by-side comparison of NVIDIA Corporation and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-11.
NVIDIA Corporation · Technology
$182.08
+59.3% upside to fair value
High Conviction
Grade A-
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
NVDA has more upside to fair value
(+59.3%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NVDA |
PFE |
| Current Price |
$182.08 |
$26.91 |
| Fair Value Estimate |
$290.00 |
$35.00 |
| Upside to Fair Value |
+59.3%
|
+30.1%
|
| Market Cap |
$4,425.5B |
$153.0B |
| Forward P/E |
—
|
9.5x
|
| EV / EBITDA |
31.4x
|
13.8x
|
| Price / Sales |
21.0x
|
2.4x
|
| Price / FCF |
46.9x
|
16.8x
|
| Revenue Growth YoY |
+65.5%
|
-1.6%
|
| Gross Margin |
71.1%
|
70.3%
|
| Operating Margin |
60.4%
|
24.7%
|
| Return on Equity |
76.3%
|
9.0%
|
| Dividend Yield |
0.02% |
6.4% |
| FCF Yield |
2.13%
|
5.9%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
NVIDIA is the foundational infrastructure layer of the AI era. Data Center revenue reached $193.7B in FY2026, up 66% YoY, powered by insatiable demand for Blackwell B200 GPUs across hyperscalers and sovereign AI programs. The company generates $96.7B in annual free cash flow with 71% gross margins and 56% net margins, making it the most profitable semiconductor business in history. At P/E 37.7x v…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
NVDA |
PFE |
| Zone Low |
$218.00 |
$25.00 |
| Zone High |
$250.00 |
$29.00 |
| In Buy Zone? |
Yes
|
Yes
|